Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viralym-C
- Development stage
- Phase 1
- Lead developer
- Kalaris Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Viralym-C is an investigational allogeneic T-cell therapy developed by AlloVir. It consists of cytomegalovirus (CMV)-specific T lymphocytes derived from healthy donors, which are banked for off-the-shelf use. The therapy is designed to treat CMV infections in patients who have undergone allogeneic stem cell transplants, a population at high risk for life-threatening viral infections due to a weakened immune system. Viralym-C aims to restore CMV-specific immunity to combat active infections, particularly those affecting organs like the lungs, gut, liver, and eyes. It is currently undergoing clinical investigation and is not approved by the FDA.
Beyond the preview
Go deeper on Viralym-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viralym-C.